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This article has been corrected since its first publication.

[Table 2](#T2){ref-type="table"} (page 5), [Table 3](#T3){ref-type="table"} (page 5) and [Table 4](#T4){ref-type="table"} (page 6) have been updated as follows:

###### Phase III trials with CDK4/6 inhibitors in HR-positive/HER2-negative MBC: median PFS and objective response rate (ORR)

  Trial         Line in the metastatic setting   Patients (n)   Treatment                                            HR for PFS   Median PFS, months   Objective response rate (ITT population) (%)
  ------------- -------------------------------- -------------- ---------------------------------------------------- ------------ -------------------- ----------------------------------------------
  PALOMA-2      1L                               666            Palbociclib + letrozole vs placebo + letrozole       0.58         24.8 vs 14.5         42.1 vs 34.7
  PALOMA-3      \>1L                             521            Palbociclib + fulvestrant vs placebo + fulvestrant   0.46         9.5 vs 4.6           19 vs 8
  MONALEESA-2   1L                               668            Ribociclib + letrozole vs placebo + letrozole        0.56         NR vs 14.7           40.7 vs 27.5
  MONARCH 3     1L                               493            Abemaciclib + NSAI vs placebo + NSAI                 0.54         NR vs 14.7           59 vs 44
  MONARCH 2     1L or 2L                         669            Abemaciclib + fulvestrant vs placebo + fulvestrant   0.55         16.4 vs 9.3          48.1 vs 21.3

###### 

Phase III trials with CDK4/6 in HR-positive/HER2-negative MBC: safety data

  Adverse event (AE)     PALOMA-2   PALOMA-3   MONALEESA-2   MONARCH 3   MONARCH 2                                                               
  ---------------------- ---------- ---------- ------------- ----------- ----------- ----- ------ ------ ----- ------ ------ ----- ------ ------ -----
  Rash                   18         1          --            NR          NR          NR    17.1   0.6    --    NR     NR     NR    11.1   1.1    0
  Fatigue                37         2          --            38          2           --    36.5   2.1    0.3   40.1   1.8    --    39.9   2.7    --
  Diarrhea               26         1          --            19          --          --    35     1.2    --    81.3   9.5    --    86.4   13.4   0
  Nausea                 35         \<1        --            29          --          --    51.4   2.4    --    38.5   0.9    --    45.1   2.7    --
  Decreased appetite     15         1          --            12.8        0.9         --    18.6   1.5    --    24.5   1.2    --    26.5   1.1    0
  Neutropenia            80         56         10            78.8        53.3        8.7   74.3   49.7   9.6   41.3   19.6   1.5   46.0   23.6   2.9
  Anaemia                24         5          \<1           26.1        2.6         0     18.6   0.9    0.3   28.4   5.8    --    29.0   7.0    0.2
  Thrombocytopenia       16         1          \<1           19.4        1.7         0.6   9      0.6    --    NR     NR     NR    15.6   2.0    1.4
  Alopecia               33         --         --            14.8        --          --    33.2   --     --    26.6   --     --    15.6   --     --
  QTcF Prolongation      --                                  --                            3.3                 --                  --            
  Increased creatinine   --                                  --                            --                  19     2.1    --    11.8   0.9    0

###### 

Phase III trials with CDK4/6 in HR-positive/HER2-negative MBC: inclusion criteria

                                         PALOMA-2 (%)   PALOMA-3 (%)   MONALEESA-2 (%)   MONARCH 3 (%)   MONARCH 2 (%)                           
  -------------------------------------- -------------- -------------- ----------------- --------------- --------------- ----- ----- ----- ----- -----
  **Menopausal status**                                                                                                                          
  Pre/perimenopausal                     0              0              21                21              0               0     0     0     16    19
  Postmenopausal                         100            100            79                79              100             100   100   100   83    81
  **Gender**                                                                                                                                     
  Female                                 100            100            100               100             100             100   100   100   100   100
  Male                                   0              0              0                 0               0               0     0     0     0     0
  **Disease-free interval**                                                                                                                      
  Newly metastatic                       38             36             0                 0               34              34    41    37    na    na
  \<12 months                            22             22             5                 2               1               3     na    na          
  \>12 months                            40             42             95                98              65              63    na    na          
  **Treatment-free interval**                                                                                                                    
  \<36 months                            na             na             na                na              na              na    28    40    na    na
  ≥36months                              63             50                                                                                       
  unknown                                9              10                                                                                       
  **Prior neo-/adjuvant chemotherapy**   48             49             40                43              44              43    38    40    60    60
  **Prior therapies for advanced BC**                                                                                                            
  1                                      0              0              38                40              0               0     0     0     38    38
  \>2 (%)                                0              0              38                34              0               0     0     0     0     0

Pages 5: The text on abemaciclib in the MONARCH 1 study has been corrected to:

Abemaciclib led to an ORR of 19.7%, CBR of 42.4% and median PFS of 6.0 months. The most common AEs all grades were diarrhea (90.2%), fatigue (65.2%), nausea (64.4%), decreased appetite (45.5%), and abdominal pain (38.6%).

Page 6. The first sentence on adjuvant setting has been corrected to:

In addition to the neoadjuvant setting, two prospective randomised phase III trials evaluating the role of the three different CDK4/6 inhibitors as adjuvant therapy when added to standard ET are currently ongoing (palbociclib: PALLAS, NCT02513394; abemaciclib: MonarchE, NCT03155997).

Page 8. The first and last author's competing interests have been updated:
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